|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
FY2017
12 months to Dec 31, 2017
|
FY2016
12 months to Dec 31, 2016
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Net Sales | |||||
| License and Other Revenue | |||||
| Total revenue | |||||
| Cost of sales | |||||
| Write-down of inventory | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (expense) income: | |||||
| Interest income | |||||
| Interest expense | |||||
| Change in fair value of warrant liabilities | |||||
| Loss on equity method investment | |||||
| Unrealized gain on equity securities | |||||
| Realized gain on equity securities | |||||
| Unrealized (loss) gain on equity securities | |||||
| Gain on extinguishment of obligation | |||||
| Other (expense) income | |||||
| Total other (expense) income | |||||
| Loss before income tax (benefit) expense | |||||
| Income tax (benefit) expense | |||||
| Net loss | |||||
| Deemed dividend on convertible preferred stock | |||||
| Net loss attributable to common stockholders | |||||
| Basic and diluted net loss per share of common stock | |||||
| Weighted average basic and diluted shares of common stock outstanding | |||||
| Other comprehensive loss: | |||||
| Net unrealized loss on available-for-sale securities | |||||
| Other comprehensive loss | |||||
| Comprehensive loss attributable to common shareholders | |||||
Loading...